A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia.
Latest Information Update: 05 May 2022
Price :
$35 *
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Fenofibrate
- Indications Hyperlipoproteinaemia type V; Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 01 Dec 2008 Pharmacodynamic results were published in the Journal of Lipid Research.
- 30 Aug 2005 New trial record.